Biotheryx Revenue

Biotechnology Research • 10201 Wateridge Circle, Suite 100, United States • 21-50 Employees

Biotheryx revenue & valuation

Annual revenue	$11,000,000
Revenue per employee	$408,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$35,200,000
Total funding	$6,000,000

Key Contacts at Biotheryx

Lawrence Zaslow

Founder/Senior Advisor

David W. Anderson

Member Board Of Directors

Arvind Shakya

Associate Director, Pharmacology

Leah Fung

Chief Executive Officer

Shenlin Huang

Senior Director Of Medicinal Chemistry

Venkat Reddy Mali

Director Of Chemistry

David Stirling

Founder And Ceo, Currently Director

Company overview

Headquarters	10201 Wateridge Circle, Suite 100, San Diego, California 92121, US
Phone number	+18585506000
Website	biotheryx.com
NAICS	541714
SIC	873
Keywords	Biotech, Cancer, Small Molecules, Inflammatory Disorders, Targeted Protein Degredation
Founded	2008
Employees	21-50
Socials

Biotheryx Email Formats

Biotheryx uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@biotheryx.com), used 88.9% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@biotheryx.com	88.9%
{first name}{last name}	johndoe@biotheryx.com	11.1%

About Biotheryx

Biotheryx is a clinical-stage biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders, including bifunctional degraders and molecular glues. Our focus is on deploying the differentiated potential of degraders towards validated targets in cancer and inflammatory disease. Members of our founding and scientific teams previously developed the IMiDs, the first U.S. Food and Drug Administration (FDA) approved modulators of Cereblon, the most widely validated E3 ligase involved in protein degradation, and we have applied our expertise in Cereblon binding to build our proprietary PRODEGY platform. Biotheryx’s clinical program, BTX-9341, a bifunctional degrader of CDK4 and CDK6, began a Phase 1 clinical trial in the third quarter of 2024. Biotheryx’s pipeline also includes BTX-10908, a first-in-class degrader of SOS1 for pan-KRAS mutant cancers and PDE4 degraders for inflammatory diseases. For more information, please visit biotheryx.com.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

Director

C-Suite

Employees by Department

Biotheryx has 14 employees across 9 departments.

Departments

Number of employees

Funding Data

Explore Biotheryx's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-05-05	19	$6,000,000

Funding Insights

$6,000,000

Total funding amount

$6,000,000

Most recent funding amount

Number of funding rounds

Biotheryx Tech Stack

Discover the technologies and tools that power Biotheryx's digital infrastructure, from frameworks to analytics platforms.

jQuery CDN

CDN

Gravity Forms

Form builders

jQuery Migrate

JavaScript libraries

Cloudflare

CDN

Twitter Emoji

Font scripts

jQuery

JavaScript libraries

Apple iCloud Mail

Webmail

HTTP/3

Miscellaneous

PHP

Programming languages

WordPress

Blogs

Google Analytics

Analytics

Draftpress HFCM

WordPress plugins

Frequently asked questions

Biotheryx is located in 10201 Wateridge Circle, Suite 100, US.

You can reach Biotheryx at +18585506000.

Biotheryx generates an estimated annual revenue of $11,000,000. This revenue figure reflects the company's market position and business performance in its industry.

Biotheryx has an estimated valuation of $35,200,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Biotheryx was founded in 2008, making it 18 years old. The company has established itself as a significant player in its industry over this time.

Biotheryx has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Biotheryx has raised a total of $6,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.